OncoSec Reports P-II Trial (KEYNOTE-695) of TAVO-EP + Keytruda (pembrolizumab) for Advanced Melanoma
Shots:
- The P-II trial evaluating TAVO-EP + Keytruda in patients with unresectable or metastatic (Stage III/IV) melanoma showed ORR (10.2%) among 98 efficacy evaluable patients with 1 post-baseline tumor assessment which did not achieve the pre-specified clinical ORR of ≥17%
- The ORR by investigator assessment of 18.8% for 101 patients prior reported as the 2EPs of the trial is lower than the BICR results for 98 patients4 had a CR, 6 with PR & 25 with SD, DCR (35.7%), and a durable response rate of ≥24wks. (8.2%), and the m-DoR (25.5mos.), was well tolerated with grade 3 TRAEs (4.8%), no patients experienced grade 4 or 5 TRAEs
- The company plan to discuss with the US FDA for a P-II randomized trial design & future development plans in the melanoma neoadjuvant setting in May 2023
Ref: oncosec | Image: oncosec
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
